<SEC-DOCUMENT>0001213900-26-043090.txt : 20260413
<SEC-HEADER>0001213900-26-043090.hdr.sgml : 20260413
<ACCEPTANCE-DATETIME>20260413172550
ACCESSION NUMBER:		0001213900-26-043090
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260413
DATE AS OF CHANGE:		20260413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		26858602

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea028604803-424b3_kazia.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(3)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-276774</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(to
Prospectus dated December 22, 2025) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>95,110
American Depositary Shares representing </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47,555,000
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Shares </B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028604803_img1.jpg" ALT="" STYLE="height: 62px; width: 200px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kazia
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the
&ldquo;Prospectus&rdquo;), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-276774), as amended, with
the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on April 13, 2026 (the
&ldquo;April 13, 2026 Form 6-K&rdquo;). Accordingly, we have attached the April 13, 2026 Form 6-K to this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered
or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should
be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus
supplement, you should rely on the information in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ADSs are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;KZIA.&rdquo; On April 10, 2026, the last reported
sale price of the ADSs on Nasdaq was $8.82 per ADS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus and the &ldquo;Risk
Factors&rdquo; in &ldquo;Item 3. Key Information-D. Risk Factors&rdquo; of our most recent Annual Report on Form 20-F, which is incorporated
by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is April 13, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of April 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 000-29962</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Kazia Therapeutics
Limited.</B></FONT><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS FORM 6-K REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Entry into Material Definitive Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This report on Form 6-K (the &ldquo;Report&rdquo;) contains information
regarding the entry into a material definitive agreement by Kazia Therapeutics Limited (the &ldquo;Company&rdquo;). On April 10, 2026,
the Company entered into a License and Commercialisation Agreement (the &ldquo;Agreement&rdquo;) with QIMR Berghofer Medical Research
Institute (&ldquo;QIMR Berghofer&rdquo;), pursuant to which the Company obtained an exclusive, worldwide license to research, develop,
manufacture, and commercialize products based on QIMR Berghofer&rsquo;s proprietary SETDB1-targeted epigenetic platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Agreement, the Company will pay QIMR Berghofer
an upfront license fee of $1,390,000 within 15 business days of execution. The Agreement also provides for the Company to pay QIMR Berghofer
a percentage of commercialization revenue received by the Company or its affiliates, with the specific percentage varying based on the
stage of development at which any product is out-licensed to a third party. The Company has agreed to use commercially reasonable efforts
to develop and commercialize at least one product under the licensed intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About the SETDB1 Platform</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SETDB1 is a histone methyltransferase that plays a key role in gene
silencing. In cancer, overexpression of SETDB1 is associated with suppression of immune signaling pathways and resistance to immunotherapy.
The licensed platform includes proprietary intellectual property directed to the inhibition of SETDB1 as a therapeutic strategy to restore
immune function in tumors and enhance the efficacy of cancer treatments. The Company believes this platform complements its existing oncology
pipeline by targeting cancer resistance mechanisms at the chromatin level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company is furnishing with this Report on Form 6-K a press release
announcing the transaction, dated April 13, 2026, as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Dr. John
Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&rsquo;s registration statements on Form F&#8209;3
(File Nos. <A HREF="https://www.sec.gov/Archives/edgar/data/1075880/000119312523296811/d866423df3.htm">333&#8209;276091</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1075880/000119312524213396/d867638df3.htm">333&#8209;281937</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1075880/000121390026029366/ea0281732-f3_kazia.htm">333&#8209;294392</A>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are furnished as part of this Form 6-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Press Release dated April 13, 2026.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Kazia Therapeutics Limited.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: April 13, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="a_001"></A>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Kazia Therapeutics Expands Oncology Platform with First-in-Class
SETDB1 Inhibitor Drug Development Platform </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sydney, Australia &ndash; April 13, 2026 &ndash; Kazia Therapeutics
Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance,
announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The platform includes use of an AI-integrated epigenetic drug discovery
engine, enabling rapid, precise, and scalable candidate generation. The lead drug candidate, MSETC, was discovered and optimized using
this AI-integrated epigenetic drug discovery engine. MSETC is a highly selective bicyclic peptide designed to target a novel, disease-associated
nuclear SETDB1 complex. By targeting SETDB1, the program is intended to restore immune signaling in tumors that have become resistant
to immunotherapy, including checkpoint inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;SETDB1 represents a compelling emerging target in oncology,&rdquo;
said Dr. John Friend, CEO of Kazia Therapeutics. &ldquo;With this acquisition, we are extending our strategy to target how cancer controls
its own behavior by addressing immune resistance at the chromatin level, one of the earliest layers of tumor immune regulation, alongside
transcriptional reprogramming with paxalisib and targeted protein degradation with our PD-L1 platform. Together, these programs position
Kazia&rsquo;s pipeline to address cancer therapy across multiple layers of tumor biology.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SETDB1 A High-Value Target in Immune Resistance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SETDB1 is increasingly recognized as a key epigenetic regulator of
tumor immune evasion and has been associated with aggressive disease and poorer clinical outcomes in several tumor types. Preclinical
studies suggest that inhibition of SETDB1 can restore interferon signaling, enhance antigen presentation, and increase tumor immune recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Internal translational research has also identified a novel SETDB1-associated
nuclear complex observed in resistant and metastatic disease settings, supporting continued development of Kazia&rsquo;s first-in-class
therapeutic approach targeting this biology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">The SETDB1 program is supported by extensive peptide screening and optimization, generating a pipeline of candidates
with strong selectivity and intracellular targeting capability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Building a Differentiated, Multi-Layered Oncology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cancer cells can evade treatment through genetic mutations, but also
by dynamically reprogramming how genes and immune signals are regulated. This adaptive behavior underpins resistance to many current therapies,
including immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kazia&rsquo;s pipeline now spans three complementary layers of cancer
control:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Chromatin-level regulation (SETDB1)  restoring immune visibility by reactivating suppressed signaling pathways</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Transcriptional reprogramming (paxalisib)  altering gene expression programs that drive tumor growth and immune suppression</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Protein-level control (PD-L1 degrader platform, NDL2)  eliminating intracellular PD-L1 and overcoming resistance mechanisms
beyond antibody-based therapies</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This integrated approach is designed to address tumor resistance at
its source and create new opportunities for combination therapies across multiple cancer types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Positioned Within a Large and Growing Oncology Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Epigenetic therapies represent a validated and expanding segment of
oncology, with multiple approved agents demonstrating clinical impact. Earlier approaches helped establish the importance of epigenetic
regulation in cancer but were often limited by broad, non-specific activity and modest clinical impact, particularly in solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advances in the understanding of tumor biology and immune resistance
now enable more precise, mechanism-driven approaches. These next-generation strategies are designed to target specific drivers of tumor
adaptation and immune evasion, with the potential for broader applicability and improved outcomes, particularly in combination with immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The global epigenetic therapeutics market is estimated to be in the
range of $15&ndash;20 billion annually and is expected to grow meaningfully over the next decade, driven by next-generation approaches
targeting immune resistance and tumor plasticity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By targeting SETDB1, Kazia is addressing a major unmet need in aggressive,
treatment-refractory cancers that account for a significant proportion of cancer-related mortality. The approach is designed to restore
immune responsiveness across multiple tumor types, particularly in advanced and metastatic disease settings where treatment options remain
limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clear Development Path and Partnering Potential</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SETDB1 program is currently in preclinical development with a defined
path toward IND-enabling studies. Kazia plans to generate translational data to support biomarker-driven development and combination strategies
with immunotherapies and targeted agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Given its broad applicability across tumor types, and its role in immune
resistance, the Company believes the program represents a compelling opportunity for early strategic partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Efficient Pipeline Expansion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kazia intends to advance the SETDB1 program in parallel with its PD-L1 degrader platform through IND-enabling
studies. By leveraging shared CRO <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">resources, coordinated study
design, and established scientific collaborations, the Company expects to achieve meaningful execution efficiencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The combined cost to advance both programs to IND readiness is expected to be approximately $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
million over 18 months, with a substantial portion of eligible expenditure expected to qualify for the Australian R&amp;D tax incentive.
This approach enables Kazia to expand its pipeline while maintaining capital discipline and preserving focus on ongoing clinical programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transaction Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreement, Kazia
has acquired global rights to the SETDB1 platform, including the lead candidate MSETC. Financial terms include an upfront payment of approximately
$1.39 million and a tiered revenue-sharing structure aligned with development progress, with no clinical or regulatory milestone obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Kazia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug
development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K
/ Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or
has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024,
and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical
trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous
system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation
for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by
the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway
mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug
Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and
July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April
2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class nuclear PD-L1 protein degrader
program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, currently in preclinical development.
For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About QIMR Berghofer:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">QIMR Berghofer is a world-leading, translational medical research institute
based in Brisbane, Australia. Established in 1945, the Institute is home to almost 1,000 scientists, clinician-scientists, support staff,
and students working across four key research programs of Cancer Research, Infection and Inflammation, Population Health, and Brain and
Mental Health. Its state-of-the-art facilities include Q-Gen Cell Therapeutics, which manufactures cell therapies. QIMR Berghofer seeks
to deliver better health and wellbeing through impactful medical research that responds to the foremost health challenges of our time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement may contain forward-looking statements, which can generally be identified as such by the use
of words such as &quot;may,&quot; &quot;will,&quot; &quot;estimate,&quot; &quot;future,&quot; &quot;forward,&quot; &quot;anticipate,&quot;
or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects,
and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding:
the potential of the SETDB1 program and epigenetic approaches to cancer treatment; Kazia's plans to advance the SETDB1 program through
IND-enabling studies; the expected timeline of approximately <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18
months to advance the SETDB1 and PD-L1 degrader programs to IND readiness; the anticipated cost of approximately $6 million to advance
both programs; expectations regarding qualification for the Australian R&amp;D tax incentive; the potential for execution efficiencies
through shared CRO infrastructure and coordinated study design; expectations regarding commercialization revenue sharing under the QIMR
Berghofer license agreement; and Kazia's broader pipeline strategy and the anticipated benefits of its three-platform approach. Such statements
are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject
to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties associated with the development of early-stage therapeutic programs, including the SETDB1
program, the risk that preclinical results may not be predictive of clinical results, risks related to the timing, cost, and outcome of
IND-enabling studies, risks related to regulatory approvals, risks related to Kazia's reliance on third-party collaborators, including
QIMR Berghofer, risks related to intellectual property protection, risks that anticipated cost savings and efficiencies may not be realized,
risks related to the availability and timing of R&amp;D tax incentive refunds, risks related to the impact of global economic conditions,
and risks related to Kazia's ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards. These
and other risks and uncertainties are described more fully in Kazia's Annual Report on Form 20-F filed with the SEC, and in subsequent
filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not
place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea028604803_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028604803_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( H<# 2(  A$! Q$!_\0
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MPHW4 +10#10 44F:7- !129HW4"N+129HS0,6BD!S2T %%%% !1110 4444
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M!\M1(K,V\GCTJ?/%97-1!2]Z2D9MG.*+@*12 4C,=N<4B/NI@)<3+!"TC'
MS7@WQ"UPZEJ1A1LH.*]6\:ZPFFZ.QSRW%?/%W=F:\=V.<MG-:Q6AE)ZEGP]>
MOI6KPLI(7=S7TGHNH+?Z;',#DD5\N.^Q@XZBO:/AGXA2ZLULI#@H,Y/>AH%)
M'IHYHQ42S'RRQ6E6;<"2,8K)HU3).U**8'W+FE#5(QU1RL%7)J2D8 CD9H2)
M9B>(5:31Y=OI7SGJRR)JDPV?Q>E?3EY");9H<<-7'7'@*VEF:9@I+'/2M$R&
MCPEUE0;BG!]J8UO,XW!#CZ5[A<> ;>1% 50 ?2H[_P '65CIK2-M&!Z5HK&;
MO<\35 .&X-!@ .X<U=UD(EXZQ 8![53#M&B\;BQQCTK16&F:?AS1WU;5XE5<
MKFOH_2K46&FV\"J!M7!KSOX9^'A;1B\D^8YS@UZ<5+!CT]!6,T6F/P=V0.*>
M#ZU' Y*8(_&I2N:Q-$]!,TQU9Q@4\+@]:'X48JT)GC'Q=4I<#(_AKS./#V?3
MG%>G?%U\7BH><K7F,3#[.1CH*U1FSTGX7PE)0WM7M"\05XU\+GWSA3P,5[/@
M>5CM42W+B$?(YIX(S@4Q,8Q0J;7+9S4%$E%%(30 -G'%0HSY((J2238N<5!D
MM(.<4T+H4=7O5L+21B0,BOGCQ9=G4-6D;=E<UZ?\3M5^QVZQ12[F88(!Z5XP
MJ/,QE>0D]<5O%&,F=IX UTZ9J4=N[84FO>HYDN;0.I^\.*^5+:=HKI;L':4.
M,>M?0G@_5UU/2H,MM9%''K420XR.F@&U,'K4X-0A?GWYZ]JE7FLC6]R2BBB@
M9',VU,US.LZL8U*@\UTERVV+\:X+7@YO,@?+6D5H<M:33!M7=?+);CO71Z??
MQ7<"HIYKAG1GC(_*MSPQ;RQ2;GS@UJ<7,VSL$5<8Q3V40H7) %- XR.M8'B7
M4I;6U(7TK&;/3P]/F+%WX@@A8J6I]M);ZQ8.O!S7E<][+-N=F-=%X*U!R"I8
MGFL&=[I\I-=>$$%Q(RKU-7]!\-I9W/G%:ZQ8UEC+&E$*K$NWKFD0ZE@"*@#8
MX%+]FB*DLOWNE2^4.$[&GC&TC^[TIV,W4N5# B*%1<$55U"S^UP%.M:J%64M
MWJ&##.<]*=M 52QY]/X;;SSA>]:NC:(+6X\QQBNK>)&DZ"LW5Y3;P$QCFLF;
M*=Q+S7X;-Q'GG%6M,U..]5\,*\JU6\EFO>IJYX=U:>&Y*9.,U<9&,XW/57 V
MX[5&-L:%L4EHYFM%=N],N<^2VVMXLX*B:9SNIZPT4Q5#WJC#K4J3!I"=IJAJ
M9=;LY'>H9<W$:(HY!K4Y[L]#TZ[%S"#5X+Z5@Z'$T=NN:VU?FL9'13D2(I#D
MU)35.33JCH=*8AJKJ7_(-N?^N9_E5HU2U5MNF7!_Z9FJAN)GROJ08:I<#_IH
M?YTVW7DDU9U#!U6?_?-5LD*V*ZNA#/8="\20Z;X.1&;G&.M>6ZWJ+ZA?.^XE
M<FHUO99=/6W+$!:I +L.3SFH));=!=2K"BDD\5['X \&Q6JI>31]1WKF/AYX
M?M;VX\R0Y(->VV\,=M$MO'P%%)@B9@L<81!@4_&(OPI% ZFD,F3M%82-HB0L
M2<5-35  ]Z=4(IA3).@I](1FFAB,<Q5$&\N&1SV%2$8XK"\3ZNFFZ=)\P!*U
MJD2V>3_$KQ"]S.;.-ONFO/B#LR?O5<U2[-[K4T['*GI1I5C)J-\L2+D&MC"1
M5V_NSNK8\+:M+IFIQD,0I8"E\1Z)/I<:$J0#6+ Y$2N/O*<T,2/JFRNH[S3X
MY(R#E1FI)\E%"_C7GGPP\0_;;3[/*V6S@5Z6H57.>_2L9(VB)"N(AGK4@%)G
MG':G5!=Q:1C@44UF"8)IB(V?YN:>Y&SD4V; 7=0A#I3L(3"F+)' KS;XC:^L
M%C);Q-AC7?:E?165E(S-C@U\Y^+-8.H:V?FRF2*M&<C+C8S!Y9.3UJ_X=L&U
M35EC"Y4$5F*208E_CX%>N?#CPQY-O'=R+R?6JN"1Z!HFG)IMA&F,<"M5R,#W
MJ.9<H O84XC]VN>U9MEV'J %XIXJ-#E<U(*S*0WO22=!]:7O22=!]:I"9XS\
M7A_IZ?[M>61M^Z8>U>I_%T_Z>G^[7E:+^Z8^U:HAGJ'PN&9A]*]IC'[H"O%O
MA2=USCVKVH#]WBID-#E4 4N,4B# H)K-FB'=J83S3L\4PGFFA,CN3\B_6JNH
M7*6-FTS'&!5R493)[<UYQ\1?$0M]/DAC;YL5:%?0\O\ %6M3:GK4J,Q*!^*R
M"#&>.E-D<2GSNK'DUT&@:*^KA\+G"YK9&,CG)AO<!.E=Y\/]<>'48;9G^7<!
M7'ZA9OIMTT<@P<TS1;QK+45GS@!LU$B4?4N[?+N7[N*L)7/^%-635-(B8-E\
M<UT"UDS>(^B@44BR*X_U8XSS6-J5@MQ&<)SZUL7+A(LGUK'GU:)&VDUM#8YZ
MJ39BMH;%EP<8K;LK-;:)>>:=;WD5P<#%7?*W8]*;9R^SU&>:8YE4CBJ/B#35
MU&UPO!Q6E.BD#IP*HW.J06H"NPKGDST\/[IYM<Z)+ Y@"D^]=%X4T0VG+=SF
MMN!K2^G+@ YK3BA2'[@K*YV3E<L"3:NP)0D9'4T].1FHYG*H2#CBM8JYYM60
M22KL.&YJHVIQH0@P3WKG-0U9_.*0MM^M8PU&1Y6"DAQWKHC3N<;K6/0%OHWR
MN0M2V[!3P<YKSQM5EB==S$MGK77:/>B:($GFB5.P*M=FXL8W;LU7O+59XWSS
MQ4RG=THE)1<^M<DXGH4I7/*M4T>>.Z:9$+8/W:O:+I$@G21HC\QYXZ5V]S%
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M@((]:I >[^"/$Z7-JD4C\FN_3:XWJ>M?,.A:M)I5VA#DKFO?/"VM1:G9*3*
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MN*,5F]C5!UILD?F*!G%.I'SCBHCN!'Y>".>*018;<&I6;(QWH3('-:M:"N&
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MB7RU_>9S0T',:\<H,.36>=2"S[<U;";(&^;H*YRV*7%^5=]@S18ES=S<DU8
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M5B.96:/(.*0#:B@C)-2O@KBD8#:*"&B(!AWXIR#GFGCYA2A>:&"0%,].*4#
MQFEZ"FYYI%6%IPIM+F@8'BC)]*"<"DW4 +D^E&3Z4FZC=0 N3Z49/I2;J-U
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M'-%%  5!]:"H(Q110*P*@7IFG8HHH&)BDV#.>:** %Q1BBB@!:*** "BBB@
CHHHH **** "D(S110 8I:** "FH@08&?QHHH =1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
